| Literature DB >> 26120586 |
Lukasz Markiewicz1, Dariusz Pytel2, Bartosz Mucha1, Katarzyna Szymanek3, Jerzy Szaflik3, Jacek P Szaflik3, Ireneusz Majsterek1.
Abstract
The aim of presented work was to analyze the impact of particular polymorphic changes in the promoter regions of the -1607 1G/2G MMP1, -1562 C/T MMP9, -82 A/G MMP12, -511 C/T IL-1β, and 372 T/C TIMP1 genes on their expression level in POAG patients. Blood and aqueous humor samples acquired from 50 patients with POAG and 50 control subjects were used for QPCR and protein levels analysis by ELISA. In vivo promoter activity assays were carried on HTM cells using dual luciferase assay. All studied subjects underwent ophthalmic examination, including BCVA, intraocular pressure, slit-lamp examination, gonioscopy, HRT, and OCT scans. Patients with POAG are characterized by an increased mRNA expression of MMP1, MMP9, MMP12, and IL-1β genes as compared to the control group (P < 0.001). Aqueous humor acquired from patients with POAG displayed increased protein expression of MMP1, MMP9, MMP12, and IL-1β compared to the control group (P < 0.001). Allele -1607 1G of MMP1 gene possesses only 42,91% of the -1607 2G allele transcriptional activity and allele -1562 C of MMP9 gene possesses only 21,86% of the -1562 T allele. Increased expression levels of metalloproteinases can be considered as a risk factor for the development of POAG.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26120586 PMCID: PMC4442285 DOI: 10.1155/2015/812503
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
The clinical characteristic of open-angle glaucoma (POAG) patients and control group.
| Parameter | Patient groups | Control group | |
|---|---|---|---|
| Percentage of the group | Gender | 38%/62% | 52%/48% |
| Hypertensiona | 54% | 70% | |
| Low blood pressureb | 40% | 29% | |
| Vascular disease | 33% | 49% | |
| Diabetes mellitus type 2d | 17% | 55% | |
|
| |||
| Mean ± SD | Age (years) | 73 ± 10 | 64 ± 1 6 |
| Intraocular pressure, IOP (mmHg) | 13.2 ± 2.9∗ | 11.9 ± 1.9 | |
| Cup disk ratio (c/d) | 0.72 ± 0.16/0.70 ± 0.16 | PNMc | |
| Rim area (RA) | 1.19 ± 0.43/1.25 ± 0.37 | PNMc | |
| Retinal nerve fiber layer (RNFL) | 0.18 ± 0.08/0.23 ± 0.22 | PNMc | |
aSystolic pressure > 140; diastolic pressure > 90 mmHg.
bSystolic pressure < 90; diastolic pressure < 60 mmHg.
cPNM: Parameter not measured.
dNo differences observed for the studied proteins expression level when DM and non-DM subjects were compared in each group (P > 0.05).
∗After the treatment: all of the patients enrolled to this study had increased IOP above 21 with the average of 23.3 ± 1.9 measurement taken during first appointment prior to antiglaucoma treatment.
The primer sequences used for mRNA expression level analysis by real-time QPCR.
| Gene | Primer sequences | Product size |
|---|---|---|
|
| F: 5′-CAGAGATGAAGTCCGGTTTTTC-3′ | 76 pz |
| R: 5′-GGGGTATCCGTGTAGCACAT-3′ | ||
|
| ||
|
| F: 5′-GAACCAATCTCACCGACAGG-3′ | 67 pz |
| R: 5′-GCCACCCGAGTGTAACCATA-3′ | ||
|
| ||
|
| F: 5′-AGTTTTGATGCTGTCACTACCG-3′ | 64 pz |
| R: 5′-CACTGGTCTTTGGTCTCTCAGAA-3′ | ||
|
| ||
|
| F: 5′-TACCTGTCCTGCGTGTTGAA-3′ | 76 pz |
| R: 5′-TCTTTGGGTAATTTTTGGGATCT-3′ | ||
|
| ||
|
| F: 5′-GAAGAGCCTGAACCACAGGT-3′ | 77 pz |
| R: 5′-CGGGGAGGAGATGTAGCAC-3′ | ||
|
| ||
|
| F: 5′-AGCCACATCGCTCAGACAC-3′ | 66 pz |
| R: 5′-GCCCAATACGACCAAATCC-3′ | ||
Figure 1Analysis of the mRNA expression levels. (a) Overall expression level of in the POAG patients compared to control group without any type of glaucoma (value after subtraction of the control group presented as fold change 2ΔΔCt); expression levels with regard to genotype in POAG patients group: (b) MMP1; (c) MMP9; (d) MMP12; (e) IL-1β; (f) TIMP1. Data presented as fold change compared to the wild type genotype (whose expression was taken as 1). Error bars represent standard deviations (SD). ∗∗∗ P < 0.001. (n = 50). There was no difference in genotypes distribution between patients with OAG and control subjects (P > 0.05). MMP1: 1G/1G = 17; 1G/2G = 17; 2G/2G = 16 MMP9: C/C = 22; C/T = 23; T/T = 5 MMP12: A/A = 23; A/G = 23; G/G = 4 IL-1β: C/C = 17; C/T = 17; T/T = 16 TIMP1: T/T = 17; T/C = 17; C/C = 16.
Figure 2Analysis of protein expression levels for MMP1 (a); MMP9 (b); TIMP1 (c); MMP12 (d); and IL-1β (e) in POAG patients (1) aqueous humor compared to the control group without any type of glaucoma (2). Error bars represent standard deviations (SD). ∗∗∗ P < 0.001. (n = 50).
Figure 3MMPs promoter activity. Plasmid constructs harboring: MMP1 2G: insertion of additional guanine in position -1607 (2G) in MMP1 gene (pGL 4.11 MMP1 2G); MMP9 T: change in position -1562 from C to T in MMP9 gene. pGL 4.11 nc: negative control (promoterless); pGL 4.13: positive control (CMV promoter). Data presented as relative luciferase units RLU calculated as FLA/RLA of the sample. Error bars represent standard deviations (SD). ∗∗∗ P < 0.001. Data from three independent experiments with independent transfections (n = 3).